IL318397A - Improved production of cd39 variants - Google Patents

Improved production of cd39 variants

Info

Publication number
IL318397A
IL318397A IL318397A IL31839725A IL318397A IL 318397 A IL318397 A IL 318397A IL 318397 A IL318397 A IL 318397A IL 31839725 A IL31839725 A IL 31839725A IL 318397 A IL318397 A IL 318397A
Authority
IL
Israel
Prior art keywords
variants
improved production
production
improved
Prior art date
Application number
IL318397A
Other languages
Hebrew (he)
Inventor
David Auslaender
Nicolas Lebesgue
Petr Obrdlik
Jo?l Alo?s Ren? TAPPAREL
Nina Wagner
Original Assignee
Novartis Ag
David Auslaender
Nicolas Lebesgue
Petr Obrdlik
Jo?l Alo?s Ren? TAPPAREL
Nina Wagner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, David Auslaender, Nicolas Lebesgue, Petr Obrdlik, Jo?l Alo?s Ren? TAPPAREL, Nina Wagner filed Critical Novartis Ag
Publication of IL318397A publication Critical patent/IL318397A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL318397A 2022-07-29 2023-07-27 Improved production of cd39 variants IL318397A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263369841P 2022-07-29 2022-07-29
US202363512316P 2023-07-07 2023-07-07
PCT/IB2023/057614 WO2024023746A1 (en) 2022-07-29 2023-07-27 Improved production of cd39 variants

Publications (1)

Publication Number Publication Date
IL318397A true IL318397A (en) 2025-03-01

Family

ID=87571500

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318397A IL318397A (en) 2022-07-29 2023-07-27 Improved production of cd39 variants

Country Status (7)

Country Link
EP (1) EP4562151A1 (en)
JP (1) JP2025524994A (en)
KR (1) KR20250044704A (en)
CN (1) CN119866373A (en)
CA (1) CA3262308A1 (en)
IL (1) IL318397A (en)
WO (1) WO2024023746A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025169047A1 (en) * 2024-02-05 2025-08-14 Novartis Ag Improved production of angptl3 mimetics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2345382A1 (en) * 1998-10-16 2000-04-27 Immunex Corporation Inhibitors of platelet activation and recruitment
WO2014097113A2 (en) 2012-12-18 2014-06-26 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
UY38299A (en) 2018-07-18 2020-02-28 Novartis Ag SOLUBILIZED APIRASES, METHODS AND USES

Also Published As

Publication number Publication date
CA3262308A1 (en) 2024-02-01
KR20250044704A (en) 2025-04-01
CN119866373A (en) 2025-04-22
EP4562151A1 (en) 2025-06-04
WO2024023746A1 (en) 2024-02-01
JP2025524994A (en) 2025-08-01

Similar Documents

Publication Publication Date Title
SG11202108304PA (en) Enzymatic production of mannose
KR102423280B9 (en) Sot-mram area-optimized design of sot-mram
GB202411655D0 (en) Application of circHIF1a
IL318397A (en) Improved production of cd39 variants
IL325330A (en) Solid forms of posiphen d-tartrate
IL288538A (en) Enzymatic production of fructose
GB202103774D0 (en) Detectiion of Ransomware
GB202105707D0 (en) Production of bacteriocins
IL317645A (en) Methods of making tolebrutinib
IL316963A (en) Process of making abaloparatide
GB202208545D0 (en) Production of immune cells
GB202112937D0 (en) Production of hepatocytes
GB202314050D0 (en) Novel form of bemcentinib
GB202313765D0 (en) Production of nanoparticles
GB202318950D0 (en) Production of immune cells
GB202511850D0 (en) Production
GB202313504D0 (en) Production of cheese
GB202219838D0 (en) Production of cheese
GB202213285D0 (en) Production of cheese
GB202504160D0 (en) Lysophospholipid production
GB202111196D0 (en) Production of immune cells
PH22021050994U1 (en) Process of making nipa syrup
GB202314542D0 (en) Production of hydro-green power
GB202216729D0 (en) Production of hydro-green power
IL315534A (en) Prodrugs of opicapone